北京万东医疗科技股份有限公司 关于 2025 年股票期权激励计划 预留部分授予结果的公告 证券代码：600055 证券简称：万东医疗 编号：临 2025-045 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 5、股票来源：公司向激励对象定向发行的本公司人民币 A 股普通股股 票。 6、激励对象名单及授予情况 重要内容提示： 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、上 海证券交易所、中国证券登记结算有限责任公司上海分公司的有关规定，北 京万东医疗科技股份有限公司（以下简称"公司"）于2025年9月26日完成 了2025年股票期权激励计划预留股票期权的授予登记工作。现将相关内容公 告如下： 一、股票期权授予的具体情况 2025年8月22日，公司召开第十届董事会第十次会议，审议通过了《关于 向2025年股票期权激励计划激励对象预留授予股票期权的议案》，鉴于1名激 励对象自愿放弃，本次预留股票期权实际向符合条件的13名激励对象授予股 票期权116万份。 本次实际授予情况如下： 股票期权授予登记完成时间：202 ...

Group 1 - The company has approved a share repurchase plan using its own funds, with a total amount ranging from RMB 30 million to 60 million, and a maximum repurchase price of RMB 25 per share, to be executed within 12 months [1] Group 2 - As of September 25, 2025, the company has repurchased 281,200 shares, representing 0.04% of the total share capital, with a total expenditure of RMB 4,998,291, excluding transaction fees [2] Group 3 - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations regarding the progress of the share repurchase [3]

Group 1 - The company, Wandong Medical, announced the repurchase of shares amounting to 281,200 shares on September 25, 2025, through centralized bidding [2] - The repurchased shares represent 0.04% of the company's total share capital [2]

证券代码：600055 证券简称：万东医疗 公告编号：2025-044 一、回购股份的基本情况 2025 年 8 月 22 日，北京万东医疗科技股份有限公司（以下简称"公司"） 召开第十届董事会第十次会议，审议通过《关于以集中竞价交易方式回购公 司股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购公司股 份，用于员工持股计划或股权激励，回购股份金额为人民币 3,000 万元（含） -6,000 万元（含），回购股份价格不超过人民币 25 元/股，实施期限为自公司 第十届董事会第十次会议审议通过本次回购方案之日起 12 个月内。具体内容 详见公司于 2025 年 8 月 23 日在上海证券交易所网站披露的《万东医疗关于 以集中竞价交易方式回购股份方案的公告》（公告编号：临 2025-038）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引 第 7 号——回购股份》等相关规定，现将公司首次回购股份情况公告如下： 北京万东医疗科技股份有限公司 关于以集中竞价交易方式首次回购股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗 ...

Group 1 - Company announced a share buyback of approximately 280,000 shares on September 25, 2025, representing 0.04% of the total share capital [1] - The highest purchase price was 17.99 CNY per share, while the lowest was 17.65 CNY per share [1] - The total amount paid for the buyback was approximately 5 million CNY [1] Group 2 - On the anniversary of "9·24", the total market value of A-shares exceeded 116 trillion CNY, indicating significant changes in the Chinese capital market [1]

格隆汇9月25日丨万东医疗(600055.SH)公布，2025年9月25日，公司通过集中竞价交易方式首次回购股 份281,200股，已回购股份占公司总股本的比例为0.04%，购买的最高价为17.99元/股、最低价为17.65元/ 股，已支付的总金额为4,998,291元（不含交易费用）。 ...

Group 1 - The company, Beijing Wandong Medical Technology Co., Ltd., has approved a share repurchase plan to buy back shares for employee stock ownership plans or equity incentives, with a total repurchase amount ranging from 30 million to 60 million yuan, at a price not exceeding 25 yuan per share, and the implementation period is until August 21, 2026 [1] - On September 25, the company conducted its first share repurchase, acquiring 281,200 shares, which represents 0.04% of the total share capital, with a total payment of 4,998,291 yuan, and the repurchase price ranged from 17.65 to 17.99 yuan per share [1] - The share repurchase is in compliance with regulations, and the company will repurchase shares opportunistically within the specified period and disclose information in a timely manner [1]

Core Viewpoint - Midea Group's medical subsidiary, Beijing Wandong Medical Technology Co., Ltd., has successfully passed expert acceptance for the "National New Material Production Application Demonstration Platform - Medical Device Material Production Application Demonstration Platform" project, marking a significant advancement in China's high-end medical equipment sector [1] Group 1 - The platform focuses on key material research and whole machine application transformation, achieving breakthroughs in multiple technical bottlenecks [1] - This initiative represents a major leap for China in high-performance medical equipment, transitioning from a follower to a leader in the field [1] - The platform was established by Wandong Medical in collaboration with 13 upstream and downstream units in the industry chain, creating an integrated innovation system encompassing "materials-components-whole machine-verification" [1] Group 2 - Over three years of construction, the platform has successfully developed six types of key materials, overcome six core component challenges, and produced six types of high-end medical equipment [1] - The most notable achievement is the successful development of the world's first liquid helium-free superconducting magnetic resonance imaging (MRI) system [1]

Investment Rating - The industry investment rating is maintained at "Outperform the Market" [2][50]. Core Insights - The medical device bidding amount in August 2025 reached 13.065 billion yuan, representing a year-on-year increase of 17% and a month-on-month increase of 2%. The total bidding amount from January to August 2025 was 110.3 billion yuan, showing a year-on-year growth of 51% [3][9]. Summary by Sections Medical Device Bidding Overview - The total bidding amount for medical devices in August 2025 was 13.065 billion yuan, with a year-on-year increase of 17% and a month-on-month increase of 2%. The cumulative bidding amount from January to August 2025 was 110.3 billion yuan, reflecting a year-on-year growth of 51% [3][9]. Domestic Brands - **United Imaging**: August bidding amount was 1.014 billion yuan, up 49% year-on-year; cumulative amount from January to August was 7.028 billion yuan, up 60% [4][13]. - **Myray Medical**: August bidding amount was 850 million yuan, up 18% year-on-year; cumulative amount from January to August was 5.904 billion yuan, up 49% [17][18]. - **Kaili Medical**: August bidding amount was 150 million yuan, up 63% year-on-year; cumulative amount from January to August was 890 million yuan, up 97% [25][26]. - **Shanwaishan**: August bidding amount was 48 million yuan, up 78% year-on-year; cumulative amount from January to August was 284 million yuan, up 194% [28][29]. - **Wandong Medical**: August bidding amount was 137 million yuan, up 200% year-on-year; cumulative amount from January to August was 936 million yuan, up 107% [31][32]. Imported Brands - **Philips**: August bidding amount was 638 million yuan, down 11% year-on-year; cumulative amount from January to August was 5.715 billion yuan, up 31% [34][35]. - **Siemens**: August bidding amount was 852 million yuan, up 41% year-on-year; cumulative amount from January to August was 7.489 billion yuan, up 49% [38][39]. - **GE Medical**: August bidding amount was 1.127 billion yuan, up 36% year-on-year; cumulative amount from January to August was 8.541 billion yuan, up 42% [41][42].

Core Viewpoint - WanDong Medical's stock has shown a significant increase in price and trading volume, indicating positive market sentiment despite a decline in net profit [1][2]. Financial Performance - For the first half of 2025, WanDong Medical reported revenue of 843 million yuan, representing a year-on-year growth of 20.46% [2]. - The company's net profit attributable to shareholders was 51.30 million yuan, which reflects a year-on-year decrease of 39.46% [2]. Stock Performance - As of September 15, WanDong Medical's stock price increased by 24.92% year-to-date, with a recent 5-day increase of 1.08%, a 20-day increase of 5.47%, and a 60-day increase of 9.29% [1]. - The stock was trading at 18.70 yuan per share with a market capitalization of 13.15 billion yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 11.69% to 26,800, while the average number of circulating shares per person increased by 13.24% to 26,201 shares [2]. - The top ten circulating shareholders include notable entities such as HuaBao ZhongZheng Medical ETF and Hong Kong Central Clearing Limited, with changes in their holdings [3]. Dividend Distribution - Since its A-share listing, WanDong Medical has distributed a total of 769 million yuan in dividends, with 267 million yuan distributed over the past three years [3]. Company Overview - WanDong Medical, established on May 12, 1997, specializes in the research, manufacturing, and sales of imaging medical devices, with 88.18% of its revenue coming from medical device sales [1].